{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:39:10Z","timestamp":1791473950963,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K15615"],"award-info":[{"award-number":["JP22K15615"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K06709"],"award-info":[{"award-number":["JP23K06709"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.leukres.2025.107704","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T22:45:39Z","timestamp":1745534739000},"page":"107704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Pre-transplant blinatumomab and\/or inotuzumab ozogamicin therapy for relapsed\/refractory acute lymphoblastic and B\/myeloid mixed phenotype acute leukemia in adults"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6009-2688","authenticated-orcid":false,"given":"Kaori","family":"Kondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-0021","authenticated-orcid":false,"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Sadato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Hirama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Sadaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kambara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Nabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2397-8073","authenticated-orcid":false,"given":"Kazuya","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atushi","family":"Jinguji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Inai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-6398","authenticated-orcid":false,"given":"Satoshi","family":"Koi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7723-0897","authenticated-orcid":false,"given":"Naoki","family":"Shingai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Haraguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Toya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8550-4181","authenticated-orcid":false,"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2025.107704_bib1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/leu.2017.283","article-title":"High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG","volume":"32","author":"Sakura","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2025.107704_bib2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"Nicola","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2025.107704_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.12225","article-title":"Outcome after first relapse in adult patients with philadelphia chromosome-negative acute lymphoblastic leukaemia","volume":"161","author":"Kako","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2025.107704_bib4","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.107704_bib5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2025.107704_bib6","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2025.107704_bib7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.leukres.2025.107704_bib8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2025.107704_bib9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2021005978","article-title":"Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab","volume":"6","author":"Wudhikarn","year":"2022","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.leukres.2025.107704_bib10","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/j.clml.2020.05.022","article-title":"Blinatumomab or inotuzumab ozogamicin as bridge to allogeneic stem cell transplantation for relapsed or refractory B-lineage acute lymphoblastic leukemia: a retrospective single-center analysis","volume":"20","author":"Stelmach","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.leukres.2025.107704_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/10428194.2019.1672057","article-title":"Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia \u2013 real-world resource use data","volume":"61","author":"Lecat","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2025.107704_bib12","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2025.107704_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.107704_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.10707","article-title":"A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia","volume":"95","author":"Weiss","year":"2002","journal-title":"Cancer"},{"issue":"5-6","key":"10.1016\/j.leukres.2025.107704_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/10428199709039047","article-title":"Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF)","volume":"25","author":"Montillo","year":"1997","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2025.107704_bib16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transpl."},{"issue":"6","key":"10.1016\/j.leukres.2025.107704_bib17","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transpl."},{"issue":"3","key":"10.1016\/j.leukres.2025.107704_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"3","key":"10.1016\/j.leukres.2025.107704_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"issue":"6","key":"10.1016\/j.leukres.2025.107704_bib20","article-title":"Allogeneic hematopoietic stem cell transplantation for adult philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in second complete remission","volume":"28","author":"Kaito","year":"2022","journal-title":"Transpl. Cell. Ther. Off. Publ. Am. Soc. Transpl. Cell. Ther."},{"issue":"5","key":"10.1016\/j.leukres.2025.107704_bib21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.bbmt.2020.01.007","article-title":"Outcomes and prognostic factors for patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter analysis","volume":"26","author":"Tachibana","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"14","key":"10.1016\/j.leukres.2025.107704_bib22","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.leukres.2025.107704_bib23","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1182\/bloodadvances.2022008032","article-title":"Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with all over the past 3 decades","volume":"6","author":"Nishiwaki","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2025.107704_bib24","article-title":"How I treat post-immunotherapy relapsed B-ALL","author":"Lamble","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2025.107704_bib25","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2025.107704_bib26","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2025.107704_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"4","key":"10.1016\/j.leukres.2025.107704_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"10.1016\/j.leukres.2025.107704_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-020-00975-2","article-title":"Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia","volume":"13","author":"Cortes","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2025.107704_bib30","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transpl."},{"issue":"13","key":"10.1016\/j.leukres.2025.107704_bib31","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/bloodadvances.2018019034","article-title":"Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia","volume":"2","author":"Stein","year":"2018","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.leukres.2025.107704_bib32","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.leukres.2025.107704_bib33","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2025.107704_bib34","article-title":"Adapting the HCT-CI definitions for children, adolescents, and young adults with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation","volume":"29","author":"Friend","year":"2023","journal-title":"Transpl. Cell Ther."},{"issue":"12","key":"10.1016\/j.leukres.2025.107704_bib35","first-page":"834","article-title":"Long-term results of allogeneic stem cell transplantation in adult Ph-negative high-risk acute lymphoblastic leukemia","volume":"28","author":"Beelen","year":"2022","journal-title":"Transpl. Cell. Ther."},{"issue":"3","key":"10.1016\/j.leukres.2025.107704_bib36","article-title":"Allogeneic hematopoietic cell transplantation for relapsed and refractory philadelphia negative B cell all in the era of novel salvage therapies","volume":"27","author":"Aldoss","year":"2021","journal-title":"Transpl. Cell Ther."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:31:20Z","timestamp":1762245080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":36,"alternative-id":["S0145212625000645"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107704","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-transplant blinatumomab and\/or inotuzumab ozogamicin therapy for relapsed\/refractory acute lymphoblastic and B\/myeloid mixed phenotype acute leukemia in adults","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107704"}}